Evidence map›Paper›PMID 39935756›Full record

ArticleContemporary oncology (Poznan, Poland)2024

Prognostic value of

Julia M Sołek, Zuzanna Nowicka, Wojciech Fendler, Rafal Sadej, Hanna Romanska, Marcin Braun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julia M SołekDepartment of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Zuzanna NowickaDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Wojciech FendlerDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Rafal SadejLaboratory of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland.
Hanna RomanskaDepartment of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Marcin BraunDepartment of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fibroblast growth factor receptor 2 (FGFR2) activation is associated with endocrine therapy resistance in luminal breast cancer (BC) Material and methods: An Results: Two clusters of ER+ IDC tumours were identified based on the stromal gene expression profile. While both clusters had similar tumour stages and hormone receptor statuses, multivariable analysis adjusted for clinical factors revealed a significant association between Conclusions: Stromal profiles modulate the prognostic significance of

Indexed as

ERFGFR2luminal breast cancerstromaTCGA

Identifiers

PMID39935756
PMCPMC11809570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.